Renaissance BioScience Corp., a global leader in yeast bioengineering, announced the appointment of Dr. James Tansey to its Board of Directors. The company focuses on technology platforms of yeast-produced RNA and yeast-derived virus-like particles (VLPs), with initial applications in crop protection and future applications in animal and human health.
Dr. Tansey is a serial entrepreneur, research academic and business leader with extensive experience in life sciences, technology commercialization, fundraising and corporate governance. He is a Professor at the University of British Columbia's Sauder School of Business and was previously a faculty member at Oxford University's Saïd Business School. Dr. Tansey is a member of the founding team at Gemina Labs, where he supports fundraising, business development and shareholder strategy. He also serves on the boards of dynaCERT Inc. and Vanadium Resources Ltd., and is a Senior Advisor to InBC, British Columbia's $500 million strategic investment fund.
Maurice Boucher, Renaissance Co-Founder and Executive Chairman, said: 'We are delighted to welcome Dr. Tansey to the Renaissance Board of Directors. James brings an outstanding combination of entrepreneurial, strategic and governance experience, together with a strong track record of helping innovative technology companies grow.' Mr. Boucher added, 'James has consistently focused on “Impact Investing” and environmental protection and sustainability throughout his exceptional career, which fits well with the positive environmental impact of Renaissance's technology platforms. His expertise will be a valuable asset for Renaissance as we continue developing and globally commercializing our biotechnology platforms.'
Dr. Tansey commented: 'Renaissance has developed an impressive portfolio of innovative technologies with significant commercial potential across agriculture, industrial biotechnology and animal and human health. I look forward to working with the Board and management team to help the company execute on its growth strategy and create long-term value.'
Dr. John Husnik, Renaissance Co-Founder, Director and CSO, commented: 'We are excited to welcome Dr. Tansey to our board. His experience building companies, securing investment, and helping innovative technologies move toward commercialization will complement our scientific expertise and support Renaissance as we continue developing and expanding our leading technology platforms.'
This appointment signals Renaissance's commitment to scaling its operations and bringing its yeast-based solutions to market. For business leaders, the move underscores the growing importance of impact investing and sustainability in biotechnology. Dr. Tansey's background in fundraising and corporate governance could help Renaissance secure further investment and partnerships, accelerating the commercialization of its RNA and VLP platforms. These technologies have the potential to reduce reliance on chemical pesticides in agriculture and could eventually address health challenges in animals and humans, offering significant environmental and economic benefits.
